The estimated Net Worth of Sophie V. Vandebroek is at least 1.01 百万$ dollars as of 6 May 2024. Sophie Vandebroek owns over 257 units of Idexx Laboratories stock worth over 722,153$ and over the last 11 years he sold IDXX stock worth over 0$. In addition, he makes 287,482$ as Independent Director at Idexx Laboratories.
Sign up
Sophie Vandebroek IDXX stock SEC Form 4 insiders trading
Sophie has made over 11 trades of the Idexx Laboratories stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 257 units of IDXX stock worth 125,997$ on 6 May 2024.
The largest trade he's ever made was exercising 9,044 units of Idexx Laboratories stock on 5 August 2019 worth over 580,534$. On average, Sophie trades about 1,065 units every 123 days since 2013. As of 6 May 2024 he still owns at least 1,473 units of Idexx Laboratories stock.
You can see the complete history of Sophie Vandebroek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sophie Vandebroek biography
Dr. Sophie V. Vandebroek Ph.D. serves as Independent Director of the Company. Previously, Dr. Vandebroek served as Vice President, Emerging Technology Partnerships for International Business Machines, Inc. (IBM) from August 2018 to August 2019 and Chief Operating Officer - IBM Research from January 2017 to August 2018. Prior to joining IBM, she was an executive with Xerox Corporation where she served as Chief Technology Officer and Corporate Vice President of Xerox Corporation and President of the Xerox Innovation Group from January 2006 to December 2016 and was Chief Engineer of Xerox Corporation from 2002 to 2005. Dr. Vandebroek was also responsible for overseeing Xerox’s global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek has been a member of the Advisory Council of the Dean of the School of Engineering at Massachusetts Institute of Technology since 2010. She is a Fellow of the Institute of Electrical & Electronics Engineers, a Fulbright Fellow and a Fellow of the Belgian-American Educational Foundation. Dr. Vandebroek holds an undergraduate degree in engineering and a master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a PhD in electrical engineering from Cornell University.
What is the salary of Sophie Vandebroek?
As the Independent Director of Idexx Laboratories, the total compensation of Sophie Vandebroek at Idexx Laboratories is 287,482$. There are 18 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of 8,309,800$.
How old is Sophie Vandebroek?
Sophie Vandebroek is 58, he's been the Independent Director of Idexx Laboratories since 2013. There are 10 older and 13 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
What's Sophie Vandebroek's mailing address?
Sophie's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Insiders trading at Idexx Laboratories
Over the last 22 years, insiders at Idexx Laboratories have traded over 238,711,289$ worth of Idexx Laboratories stock and bought 24,695 units worth 3,109,424$ . The most active insiders traders include Stuart Essig、Johnny D Powers、Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of 4,641,291$. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth 234,685$.
What does Idexx Laboratories do?
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
What does Idexx Laboratories's logo look like?
Complete history of Sophie Vandebroek stock trades at Idexx Laboratories
Idexx Laboratories executives and stock owners
Idexx Laboratories executives and other stock owners filed with the SEC include:
-
Jonathan Ayers,
Director -
Jonathan Mazelsky,
President, Chief Executive Officer, Director -
Brian McKeon,
Chief Financial Officer, Executive Vice President, Treasurer -
Kathy Turner,
Corporate Vice President and Chief Marketing Officer -
Jonathan J. Mazelsky,
Pres, CEO & Director -
Sharon Underberg,
Corporate Vice President, General Counsel, and Corporate Secretary -
Michael Lane,
Executive Vice President, General Manager, Reference Laboratories and Information Technology -
Brian P. McKeon,
CFO, Exec. VP & Treasurer -
Giovani Twigge,
Chief Human Resource Officer, Corporate Vice President -
Dr. Nimrata Khatra Hunt P.E., Ph.D.,
Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations -
Michael J. Lane,
Exec. VP and GM of Reference Laboratories & Information Technology -
James F. Polewaczyk,
Exec. VP & Chief Commercial Officer -
Sharon E. Underberg,
Exec. VP, Gen. Counsel, & Corp. Sec. -
Lawrence Kingsley,
Independent Chairman of the Board -
M. Anne Szostak,
Independent Director -
Daniel Junius,
Independent Director -
Bruce Claflin,
Independent Director -
Rebecca Henderson,
Independent Director -
Sophie Vandebroek,
Independent Director -
Stuart Essig,
Independent Director -
Sam Samad,
Independent Director -
Jonathan W. Ayers,
Sr. Advisor & Director -
Asha Collins,
Independent Director -
James Polewaczyk,
Executive Vice President and Chief Commercial Officer -
Tina Hunt,
Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations -
Dr. Martin Smith Ph.D.,
Exec. VP & CTO -
Ken Grady,
Sr. VP & Chief Information Officer -
Martin Smith,
Exec. VP & CTO -
Jeffery D. Chadbourne,
Sr. Director of Accounting & Financial Reporting -
John Hart,
Sr. VP of Worldwide Operations -
Barry C Johnson,
Director -
Thomas Craig,
Director -
William End,
Director -
Jacqueline Studer,
CVP, Gen. Counsel & Secretary -
Thomas J Dupree,
Corporate Vice President -
Michael J Williams,
Corporate Vice President -
Daniel V Meyaard,
Corporate Vice President -
Conan R Deady,
Vice President and Secretary -
Joseph V Vumbacco,
Director -
William E Iii Brown,
Corporate Vice President -
William B. Goodspeed,
Corporate Vice President -
Robert J Murray,
Director -
Jeffrey Fiarman,
EVP, GEN COUNSEL & SECRETARY -
Ali Naqui,
Vice President -
Johnny D Powers,
Corporate Vice President -
Errol B Desouza,
Director -
William C Wallen,
SVP & Chief Scientific Officer -
Quentin J Tonelli,
Vice President -
S Sam Fratoni,
Vice President -
Irene C Kerr,
Corporate Vice President -
Robert S Hulsy,
Vice President -
Laurel E Labauve,
Vice President -
Merilee Raines,
Vice President,CFO & Treasurer -
James L Jr Moody,
Director -
Jennifer A Joiner,
Corp VP CAG N American CommOps -
Louis W Pollock,
Senior Vice President -
Erwin R Jr Workman,
Executive Vice President -
Nimrata Hunt,
Executive Vice President -
Irene Chang Britt,
Director -
Martin Alexander Smith,
Executive Vice President -
Michael Perkins Johnson,
EVP and CHRO -
George Fennell,
SVP, Chief Revenue Officer -
Michael G Erickson,
Executive Vice President -
Michael Schreck,
Executive Vice President